A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Femhrt Online, Description, Chemistry, Ingredients - Norethindrone acetate and ethinyl estradiol
Femhrt Online, Description, Chemistry, Ingredients - Norethindrone acetate and ethinyl estradiol
WARNING
Estrogens and progestins should not be used for the prevention
of cardiovascular disease.
The Women’s Health Initiative (WHI) study reported increased
risks of myocardial infarction, stroke, invasive breast cancer, pulmonary
emboli, and deep vein thrombosis in postmenopausal women during 5 years
of treatment with conjugated equine estrogens (CE 0.625 mg) combined with
2.5mg medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see
WARNINGS).
Other doses of conjugated estrogens with medroxyprogesterone,
and other combinations of estrogens and progestins were not studied in
the WHI and, in the absence of comparable data, these risks should be
assumed to be similar. Because of these risks, estrogens with or without
progestins should be prescribed at the lowest effective doses and for
the shortest duration consistent with treatment goals and risks for the
individual woman.
|
DESCRIPTION
femhrtÒ 1/5 is a continuous
dosage regimen of a progestin-estrogen combination for oral administration.
Each white D-shaped tablet contains 1 mg norethindrone
acetate [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17a)-]
and 5 mcg ethinyl estradiol [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol,
(17a)-]. Each tablet also contains calcium stearate,
lactose monohydrate, microcrystalline cellulose, and cornstarch.
top
